tbuckley/cabot-search huggingface dataset:
The prevalence of KRAS<sup>G12C</sup> mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.
Authors: Kyaw Thein, Kimberly Banks, Jennifer Saam, Victoria M. Raymond, Jason Roszik, Funda Meric-Bernstam, Filip Janku, David S. Hong
Journal: Journal of Clinical Oncology (2020)

3547 Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most commonly mutated proto-oncogene identified in cancer and still remains an arduous therapeutic challenge. Recently, KRAS G12C mutation has become special interest since it has now been considered potentially druggable after the introduction of covalent small-molecule KRAS G12C inhibitors. Advances in next-generation sequencing (NGS) and embracing utilization of ctDNA have uncovered more genetic alterations in many cancers. We present a comprehensive analysis on the prevalence of KRAS G12C mutations identified by ctDNA. Methods: We conducted a 5-year (July 2014 to June 2019) retrospective review of ctDNA NGS analysis in the Guardant360 CLIA database inclusive of treatment-naïve and previously treated patients with metastatic solid tumors. Data were retrieved from the 80,911 unique patients with ctDNA detected. Clonality and co-occurrence of cancer type were analyzed. Clonality was defined as variant allele fraction(AF) / maximum somatic AF in the sample. Results: 80,911 patients, which included more than 100 tumor histologies, were identified. 2,985 patients (3.7%) with &gt; 40 tumor types had KRAS G12C mutations identified in ctDNA. KRAS G12C prevalence by cancer type were as follows: sarcomatoid lung carcinoma (13.5%), lung cancer NOS (9%), large cell lung carcinoma (9%), lung adenocarcinoma (7.4%), NSCLC (6.9%), carcinoma of unknown primary (CUP) (4.1%), lung carcinoid (4%), CRC (3.5%), squamous cell lung carcinoma (2%), small cell lung carcinoma (1.5%), pancreatic ductal adenocarcinoma (PDAC) (1.2%), cholangiocarcinoma (1.2%), bladder cancer (0.6%), ovarian cancer (0.6%) and breast cancer (0.3%). 53 additional patients with KRAS G12C were identified across 24 other tumor types. The KRAS G12C mutation was found to be clonal (clonality &gt; 0.9%) in the majority of patients with lung adenocarcinoma, NSCLC, CUP, squamous cell lung carcinoma, and PDAC, compared to patients with CRC and breast cancer who had bimodal distribution of clonal and sub clonal mutations. Conclusions: To our knowledge, this is the largest analysis on the prevalence of KRAS G12C mutations identified by ctDNA. Our study demonstrated the feasibility of utilizing ctDNA to identify KRAS G12C mutations across solid tumors with the highest prevalence in lung cancer as previously reported in tissue. The clonality information available from ctDNA-based genotyping may provide insights into the clinical efficacy of targeting KRAS G12C in different tumor types.
Circulating tumor DNA dynamics as prognostic and predictive biomarkers of response to pembrolizumab in patients with virally-related tumors (VRT) treated within the INSPIRE study.
Authors: Marc Oliva Bernal, Zhihui (Amy) Liu, Marco Adelmo James Iafolla, Anna Spreafico, Sarah Jennings, Albiruni Ryan Abdul Razak, Cindy Yang, Scott Victor Bratman, Dax Torti, Trevor John Pugh, Lillian L. Siu, Aaron Richard Hansen
Journal: Journal of Clinical Oncology (2020)

3068 Background: We previously showed a correlation between circulating tumor DNA (ctDNA) dynamics and response to pembrolizumab in a cohort of mixed tumors treated in the INSPIRE study (Yang et al, ESMO 2019). We investigated the prognostic and predictive value of ctDNA dynamics in patients (pts) with VRT. Methods: Pts with VRT (HPV+ squamous cell carcinoma (SCC), EBER+ nasopharyngeal carcinoma (NPC) and MCPyV+ Merkel carcinoma (MC)) and a control cohort of non-VRT (HPV- head and neck SCC) treated with single-agent pembrolizumab were selected for the analysis. ctDNA was assayed at baseline and start of cycle 3 using a pt-specific amplicon-based NGS assay (Signatera). Samples were considered ctDNA positive if ≥2 of 16 pt-specific targets met the qualifying confidence score threshold. Whole exome sequencing (WES) performed in baseline tumor tissue; presence of HPV, EBV and MCPyV in tumor determined through bioinformatic analysis of WES data (VirusFinder, PMID23717618). Changes in tumor size (mm) and response data using RECIST 1.1 were collected. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. Results: Twenty pts with VRT (HPV+ head and neck = 8, cervical = 2 and anal = 2 SCC; EBER+NPC = 2; MC = 6) and 11 pts with non-VRT were included. Median follow-up: 11 months (0,5-11). Treatment response: VRT 6 responders (CR + PR + SD &gt; 18weeks) and 14 non-responders (SD &lt; 18 weeks + PD); non-VRT 3 responders and 8 non-responders. Median OS and PFS for all pts were 10.61 and 3.2 months, respectively. No differences in PFS (p = 0.60) nor OS (p = 0.66) were observed among responders between VRT and non-VRT. Among non-responders, VRT had significantly higher OS but not PFS when compared to non-VRT (HR 0.30, p = 0.01 and HR 0.82 p = 0.62, respectively). VRT had quantitatively higher ctDNA at baseline vs non-VRT (Mean 7.9 vs 0.4 ng, p &lt; 0.001). ΔctDNA (Change in ctDNA between baseline and cycle 3) strongly correlated with changes in tumor measurements and response by RECIST 1.1 (Spearman Rho = 0.75) and was associated with survival regardless of viral status (Table). Conclusions: ΔctDNA strongly correlated with changes in tumor response and survival in both VRT and non-VRT. Higher baseline ctDNA was found in VRT. Correlation with circulating viral DNA and radiomics analyses is on-going. [Table: see text]
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
Authors: Weimin Li, Athena Matakidou, Zara Ghazoui, Han Si, Sophie Wildsmith, Nassim Morsli, Helen Mann, Magdalena Wrona, Melissa de Los Reyes, Rajiv Raja, Craig Barker, Jessica Whiteley, Qu Zhang, Jerome Fayette, Dan Paul Zandberg, Ricard Mesia, Lillian L. Siu
Journal: Journal of Clinical Oncology (2020)

6548 Background: Baseline tumor and germline biomarkers in R/M HNSCC were analyzed for predictive potential in pts benefitting from D or D+T. Methods: In HAWK (NCT02207530), 112 pts (PD-L1 tumor cells [TC]≥25%) received D (10 mg/kg Q2W for ≤12 m); in CONDOR (NCT02319044), 67 pts (PD-L1 TC &lt; 25%) received D (10 mg/kg Q2W for ≤12 m), 133 pts received D+T (D 20 mg/kg Q4W, T 1 mg/kg Q4W for ≤12 m), and 67 pts received T (10 mg/kg Q4W [7 doses] then Q12W [2 doses] for ≤12 m) VENTANA PD-L1 (SP263) Assay determined PD-L1 status. Paired FFPE archival tumor and PBMC samples (as germline control) in the HAWK and CONDOR trials were evaluated by whole exome sequencing (WES). Tumor mutation burden (TMB) was number of somatic mutations/megabase. HLA class I types were obtained via WES of PBMCs (CONDOR only). HPV and neutrophil-to-lymphocyte ratio (NLR) were tested locally in CONDOR. Wilcoxon, log-rank tests, and COX-PH models were used. Pooled D &amp; D+T data were analyzed unless noted. Results: 153 pts had paired evaluable FFPE tumor and PBMC samples (HAWK, n = 48; CONDOR, n = 105). TMB distributions were similar between studies ( P= 0.43). TMB correlated with smoking ( P= 0.02) but not HPV ( P= 0.24), NLR ( P= 0.66), or PD-L1 status ( P= 0.43). Overall, high TMB (≥upper tertile) trended with longer OS vs low TMB in all evaluable pts (N = 153; 9.0 vs 5.6 m; HR = 0.70; 95% CI = 0.48-1.01); P= 0.06). In HAWK, there was no association of TMB with OS. In CONDOR, pts (D and D+T arms) with high TMB vs low had significantly longer OS (N = 76; 16.3 vs 5.3 m; HR = 0.53; 95% CI = 0.31-0.92). TMB and OS association was further assessed by increasing TMB cutoffs. Improved HRs trended with higher cutoffs; cutoffs ≥upper quartile significantly linked to OS.TMB was not associated with PFS or ORR. Pts with low PD-L1 and low TMB had worse OS compared to pts with high PD-L1 or high TMB. Pts with high NLR (≥median) and low TMB had significantly worse OS than pts with low NLR and high TMB (HR = 2.63, P&lt; 0.001). Analysis of germline HLA alleles revealed significantly poorer survival for carriers of the HLA-B*15:01 allele (9.4%) (HLA-B variant status did not affect TMB and OS association in CONDOR). Germline HLA heterozygosity did not impact OS. Pts with mutations in ATM (5%), a DNA damage repair gene, also trended with prolonged OS. Conclusions: TMB is a possible predictive biomarker of IO HNSCC therapy. Combined analysis of NLR and TMB may provide additional PD-L1 data in assessing pts most likely to have long-term benefit. Clinical trial information: NCT002207530, NCT02319044 .
Clinical characteristics of patients with ketosis-onset diabetes
Authors: Bo Liu, Ye Ji, Ying-di Shen, Hai-rong Tian, Zhi-yun Li
Journal: BMJ (2012)

A total of 105 patients with ketosis-onset diabetes were divided into four groups (A+B-,A + B +,A - B -,A - B +) based on the results of islet-associated autoantibodies (A +,A - ) and β-cell function (B +,B - ).Nearly 94％ patients in the A -B + group and 1/10 patients in the A - B - group were non-insulin dependent.While in the A + B - and A + B + groups,the detection rates of subsequent non-insulin dependency were 20％ and 58％,respectively.Among the four groups,patients in the A - B + groups had a lower level of IL-6 and a higher level of TNF-α. Patients in the A + B - and A + B + groups had a higher level of IL-18.Our study indicates that patients with ketosis-onset diabetes may present different clinical characteristics. Evaluate the islet-associated autoantibodies and pancreatic β-cell function may be helpful to the clinical diagnostic and therapeutic strategies in diabetes.

Key words: 
Diabetic ketoacidosis;  Insulin-secreting cells metabolism
Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
Authors: Jianbo Tian, Xianglin Yuan, Jun Xiao, Qiang Zhong, Chunguang Yang, Bo Liu, Yimin Cai, Zequn Lu, Jing Wang, Yanan Wang, Shuanglin Liu, Biao Cheng, Jin Wang, Ming Zhang, Lu Wang, Siyuan Niu, Zhi Yao, Xiongbo Deng, Fan Zhou, Wei Wei, Qinglin Li, Xin Chen, Wenqiong Chen, Qin Yang, Shiji Wu, Jiquan Fan, Bo Shu, Zhiquan Hu, Shaogang Wang, Xiang-Ping Yang, Wenhua Liu, Xiaoping Miao, Zhihua Wang
Journal: The Lancet Oncology (2020)
Phloroglucinol effectively alleviates abdominal pain in acute gastroenteritis
Authors: Ai-fang Yang, Bo-jia Zhang, Min You, Jian-hong Han, Song-hua Wei
Journal: BMJ (2012)

The aim of the study was to evaluate the efficacy and safety of phloroglucinol in treatment of abdominal pain caused by acute gastroenteritis.Three hundred patients with acute abdominal pain were randomly assigned to receive 80 mg intravenous infusion of phloroglucinol injection ( treatment group,n =150 ) or 10 mg anisodamine injection (control group,n =150).The pain intensity was estimated by the VAS scores before and after the injection,meanwhile adverse reactions were also recorded.The results showed that the pain intensity was relieved significantly after 1h of the injection in both groups(P ＜0.01).The effective rate of phloroglucinol was 84.1％ (126/150),while that of anisodamine was 80.0％ (120/150).The adverse reactions of treatment group were lower than that of control group( all P ＜0.01).The results indicate that phloroglucinol can effectively relieve abdominal pain caused by acute gastroenteritis with safety.

Key words: 
Phloroglucinol; Abdominal pain
胃黏膜瘤变腺腔内嗜中性粒细胞的测定与胃腺癌的关系
Authors: 姚海山, 李晓英, 任乾锋, 李亚琼, 张玉君, 赵俊
Journal: BMJ (2011)

回顾分析2001年1月至2009年12月山西省晋城市人民医院收治的173例经病理检查诊断为高级别胃上皮内瘤变(GIN)患者的胃黏膜活检组织，探讨高级别GIN瘤变腺腔内嗜中性粒细胞与胃腺癌的关系，报告如下。 关键词：粒细胞
院前手法转复阵发性室上性心动过速的体会
Authors: 杨志新, 董艳丽
Journal: BMJ (2004)

阵发性室上性心动过速(PSVT)是院前急救中常见的心血管急症,用刺激迷走神经的物理方法实施转复,方法简便易行,有一定的效果.在院前急救的实践中,我们采用吹气法与颈动脉窦按摩相结合转复PSVT,较单一方法转复率明显提高,取得了较为满意的疗效。
Skeletal muscle density as a positive predictive factor for nivolumab therapy in patients with metastatic renal cell carcinoma.
Authors: Meltem Ekenel, Murat Sari, Samil Aliyev, Mert Basaran
Journal: Journal of Clinical Oncology (2020)

e17107 Background: Immunotherapy has shown promising clinical responses in patients with metastatic Renal Cell Carcinoma (mRCC) at second-line therapy. Since objective response rates are highly variable, it is utmost important to identify patients who may benefit from immunotherapy to avoid unnecessary adverse effects and costs. Therefore, predictive as well as prognostic markers need to be studied extensively. To our knowledge, none of the body composition measurements such as fat content or skeletal muscle density have been assessed for this purpose. The objective of the current study is to analyze whether skeletal muscle (either muscle mass or muscle density) and adipose tissue play a prognostic role in patients with mRCC who were treated with immunotherapy at second line. Methods: We retrospectively analyzed 14 patients with mRCC who were progressed after tyrosine kinase inhibitor therapy and treated with Nivolumab between March 2016 and September 2019. Skeletal muscle density (SMD), skeletal muscle and adipose tissue were assessed with computed tomography imaging. Overall Survival (OS) and Progression Free Survival (PFS) were estimated by using the Kaplan-Meier method. Results: The median OS was 13,1 months and it was strongly associated with SMD; the median OS was significantly longer in patients with high SMD compared to patients with low SMD (6,9 months vs 18,5 months; P &lt; 0,05). Also in our analysis, SMD separated the intermediate-risk group into 2 groups with different median OS periods, ranging from 8,1 months (95% confidence interval [95% CI], 5,1 months-11,1 months) in patients with intermediate-risk Heng score and low SMD to 21,5 months (95% CI, 14 months-27 months) in patients with an intermediate-risk Heng score and high SMD. Other parameters calculated for adipose tissue or skeletal muscle did not cause any significant change in survival analysis. Conclusions: High SMD appears to be associated with improved outcome in our small patient population. It could be a predictive factor when immunotherapy, Nivolumab, is considered for therapy of mRCC patients at second line.
Phase I study of regorafenib and sildenafil in advanced solid tumors.
Authors: Andrew Stewart Poklepovic, Sarah W. Gordon, William P. McGuire, Leroy R. Thacker, Xiaoyan Deng, Mary Beth Tombes, Ellen Shrader, Alison A. Ryan, Maciej Kmieciak, Paul Dent
Journal: Journal of Clinical Oncology (2020)

3593 Background: Regorafenib (R) is an oral multikinase inhibitor with anti-angiogenic properties approved for use in several solid tumors. Sildenafil (S) is an oral phosphodiesterase-5 (PDE5) inhibitor that interacts synergistically with R in both short-term and colony formation assays to kill multiple cancer cell types. Mechanistic studies identified that PDE5 knockdown enhances R lethality, suggesting a direct target effect for S. Methods: A single-center, open-label, dose-escalation study was conducted in adults with advanced solid tumors. Patients (pts) took R (120 or 160 mg) and S (50 or 100 mg) once daily days 1 through 21 of each 28-day cycle. Pts remained on study treatment until progression or excessive toxicity, with response assessments every 8 wks. The maximum tolerated dose (MTD) was defined as the maximum tested dose with ≤1/6 pts experiencing dose-limiting toxicity (DLT), with Cycle 1 as the DLT observation period. Results: 32 pts were enrolled and 29 treated at 3 dose levels (DLs). Median duration of treatment was 8 (range 2 – 101) wks. One of 6 evaluable pts treated at DL2 (160 mg R + 50 mg S) experienced DLT (grade 4 lipase increase). One of 12 evaluable pts treated at DL3A (160 mg R + 100 mg S, the MTD) experienced DLT (grade 3 rash and grade 3 muscle pain). The toxicity profile was generally consistent with that seen in R monotherapy at FDA-approved doses. 10 pts had a best response of progressive disease (PD). 14 pts had a best response of stable disease (SD), 5 of whom had stable disease duration &gt; 24 wks. 5 treated pts were not evaluable for response. Notably, 2 pts with ovarian cancer and 1 with cervical cancer had stable disease &gt; 24 wks. Analyses of correlative studies to examine pharmacokinetics and drug combination pharmacodynamic effects are underway. Conclusions: The combination was well-tolerated. The recommended phase 2 dose is 160 mg R + 100 mg S. Objective responses were not observed, but prolonged stable disease was seen in a subset of pts. Encouraging disease control was seen in gynecologic cancers. Dosing up to 100 mg S is safe concurrently with standard doses of R, and may be considered as an adjunct to R in future trials. Evaluation of R+S in gynecologic cancers warrants further consideration. Clinical trial information: NCT02466802 . [Table: see text]
Management strategies of ectopic pregnancy and reproductive outcomes: a report of 648 cases
Authors: Jinping Sun, Qingbo Fan, Yuwen He
Journal: BMJ (2014)

Objective
To explore the reproductive outcomes of different management strategies of ectopic pregnancy.


Methods
A retrospective cohort study was performed for 648 consecutive patients with a diagnosis of ectopic pregnaney between June 2011 and september 2013. The follow-ups were conducted telephone interviews of pregnancy outcomes after various treatments.


Results
The subsequent intrauterine pregnancy rates after surgical, medical and expectant managements were 89(65.0%), 35(79.6%) and 6(54.5%) the intrauterine pregnancy was higher for medical treatment than that for surgical treatment (P<0.05). The subsequent infertility rate after surgical, medical and expectant management were 4.5%, 36.4%, 19.0%. The subsequent infertility rate after medical treatment was lower than that for surgical and expectant managament (P<0.05). The re-ectopic pregnancy rates of laproscopic versus abdominal operation were [11 (11.7%), 13(30.2%)] with significant difference (P<0.05). And abdominal operation was higher than laproscopic operation.


Conclusion
For younger ectopic pregnancy patients, medical treatment shold be as possible as we can. If operation is necessary, laproscopic operation is preferred.


Key words: 
Pregnancy, tubal; Pregnancy outcome; Fertility
Deoptimized influenza virus for treatment of TNBC and induction of anticancer immunity in the EMT6 mouse model.
Authors: Marcin Stawowczyk, Charles Brandon Stauft, Ying Wang, Steffen Mueller, John Robert Coleman
Journal: Journal of Clinical Oncology (2020)

e13109 Background: Triple negative breast cancer (TNBC) is resistant to classical hormone-based therapy, prone to relapse and aggressive metastasis. Oncolytic viruses (OVs) when injected into the tumor, can promote local lysis of tumor cells and drive presentation of tumor antigens, thereby making tumors visible to the immune system. CodaLytic is a re-coded influenza A virus that has a high frequency of disfavored codons and codon pairs which attenuate the virus yet preserve all antigens and immune stimulation properties of the wild type influenza virus. CodaLytic is produced from the same master virus seed as CodaVax, a universal influenza vaccine candidate currently in Phase I clinical trials under a US IND. Methods: BALB/c mice were implanted with EMT6 mouse TNBC cells into a mammary fat pad. Six days post-implantation, when tumors became palpable, treatment was initiated by intratumoral administration of PBS (mock) or CodaLytic (10 8 PFU in 50 µL). Mice were treated three times a week for a total of three weeks. Tumor growth was monitored daily for 33 days and animals were euthanized if the tumor volume exceeded 500 mm 3 . Survivors were challenged via flank or intravenous (IV) injection of EMT6 cells. Two weeks after IV challenge, lungs were removed and compared to the lungs of control mice. Results: At the end of the initial experiment (day 33), 80% of CodaLytic-treated mice were alive with 70% of survivors being tumor-free as compared to mock, of which none survived. Survivors on day 33 had a median decrease in tumor size of 75%. CodaLytic stimulated lasting anti-tumor immunity as 100% of CodaLytic-treated survivors failed to establish tumors following challenge with EMT6 cells via flank injection. To model metastasis, surviving treated mice were also challenged with EMT6 cells delivered 2x10 4 cells IV. IV challenged mice had over 10-fold fewer nodules in their lungs as compared to naïve controls and 40% of the animals remained tumor free, whereas 100% of the control animals developed tumors. Additionally, CodaLytic-treated survivors showed no weight loss after IV re-challenge compared to controls which lost an average of 12% body mass. Conclusions: CodaLytic OV treatment of TNBC increased survival, led to complete tumor clearance in the EMT6 mouse model, and induced systemic anti-tumor immunity that has potential for preventing and treating metastatic disease.
Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.
Authors: Petri Bono, Reetta Virtakoivu, Felix Vaura, Panu Jaakkola, Shishir Shetty, Alain Thibault, Maja J.A. de Jonge, Anna Rachel Minchom, Yuk Ting Ma, Christina Yap, Debbie Robbrecht, Annika Pasanen, Tanja Skytta, Romillie Cruz, Markku Jalkanen, Sirpa Jalkanen, Jami Mandelin, Matti Karvonen, Jussi Koivunen, Maija Hollmen
Journal: Journal of Clinical Oncology (2020)

3097 Background: The scavenger receptor CLEVER-1 mediates the clearance of “unwanted” self-components and is highly expressed on tumor associated macrophages (TAMs). CLEVER-1 expression is associated with immunotherapy resistance and poor survival in several cancers. Pre-clinical studies demonstrate that CLEVER-1 inhibition increases TAM pro-inflammatory cytokine secretion and antigen presentation reactivating CD8 T cell responses with robust anti-tumor activity. Targeting CLEVER-1 could therefore overcome the immunosuppressive tumor microenvironment and has led to the development of FP-1305, a humanized anti-CLEVER-1 IgG4-antibody. Methods: The MATINS (Macrophage Antibody To INhibit immune Suppression) trial is a multicenter first-in-human phase I/II study (NCT03733990) to assess the tolerability, safety and preliminary efficacy of FP-1305 in patients (pts) with advanced cancers including immunotherapy-refractory melanoma, cholangiocarcinoma, hepatocellular carcinoma, ovarian cancer, colorectal (CRC), and pancreatic ductal adenocarcinoma. Part 1 consisted of a dose escalation phase; 30 pts (median age 65, range 30-81) were enrolled to examine 5 dose levels (0.1, 0.3, 1.0, 3.0, 10 mg/kg), to determine the optimal dose of FP-1305 for Parts 2 and 3. Two-stage time-to-event continual reassessment method (TITE-CRM) was utilized for the dose escalation in Part 1. Pts received 1-8 cycles (median 3) of FP-1305 Q3w. FP-1305 was well tolerated without dose-limiting toxicities. A consistent increase in blood NK cells, CD8/CD4 T cell ratio, B cells and a decrease in regulatory T cells was demonstrated. FP-1305 dosing led to the activation (CD25 + ) and Th1 skewing (CXCR3 + ) of T cell populations including increase in effector CD8 T-cells with downregulation of several inhibitory immune checkpoint molecules (PD-1, PD-L1, CTLA-4, and LAG3). Increased circulating IFNɣ levels were detected, with the highest levels in a heavily pretreated metastatic, microsatellite stable (MSS) colorectal cancer patient leading to a partial tumor response (-52%). FP-1305 is the first macrophage checkpoint inhibitor candidate promoting immune switch with promising tolerability and clinical anti-tumor activity. FP-1305 represents a novel treatment option to provoke immune response especially in non-inflamed tumors. Full safety, pharmacokinetic and efficacy results of MATINS trial (Part 1) will be presented for the first time in a final late breaking abstract. Clinical trial information: 2018-002732-24 .